Atrial Fibrillation Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are scheduled to have a catheter ablation procedure for atrial fibrillation (an irregular heartbeat) because medication has not worked well enough to control it.
• People with a stroke risk score (called CHA2DS2-VASc, not counting gender) of between 1 and 4.
• People who are currently taking one of these blood thinners — rivaroxaban, dabigatran, apixaban, or edoxaban — and plan to continue taking one of them long-term to reduce stroke risk from atrial fibrillation.
• People aged 19 to 89 years (inclusive) who are willing to voluntarily sign a consent form to participate.

Who may not be able to join:

• People who have previously had a stroke or a transient ischemic attack (sometimes called a "mini-stroke").
• People with certain bleeding conditions or diseases that make blood-thinning medication unsafe, including clotting disorders, significant gastrointestinal bleeding within the past 6 months, a history of bleeding in the brain or eye, or who have received clot-dissolving treatment within 48 hours before joining the study.
• People who have other medical reasons that prevent them from safely taking blood-thinning medication.
• People whose heart and circulation are unstable at the time of joining, such as those in cardiogenic shock, with a serious heart rhythm problem that has not responded to treatment, or with very severe heart failure (confirm with trial site).
• People with severely low red blood cell levels (haemoglobin below 8 g/dL) or who have received a blood transfusion within the four weeks before the first visit.
• People with a very low platelet count (below 50,000/mm³), which affects the blood's ability to clot.
• People who are on dialysis or who have very severe kidney disease (with a creatinine clearance below 15 ml/min).
• People with severe liver disease, including conditions such as bleeding from varicose veins in the oesophagus, fluid build-up in the abdomen, confusion caused by liver failure, or jaundice.
• People for whom implanting a small heart-monitoring device under the skin (called an implantable loop recorder) would not be safe, such as those with a weakened immune system or a condition that affects wound healing.
• People with severe heart valve disease, an artificial heart valve, a repaired mitral valve, or rheumatic mitral valve narrowing (regardless of how severe it is).
• People who need to take blood-thinning medication long-term for a reason unrelated to an irregular heartbeat.
• People who have a condition called hypertrophic cardiomyopathy (a thickening of the heart muscle).
• People considered to be at high risk of stroke from causes other than the heart, such as significant narrowing of the arteries in the neck (confirm with trial site).
• People who are currently taking warfarin or coumadin (older types of blood-thinning medication).
• People who are currently taking two different antiplatelet medications at the same time (confirm with trial site).
• People who are pregnant, breastfeeding, or women of childbearing age who are not willing to use a reliable form of contraception throughout the study. Acceptable methods listed include condoms, injectable or implantable contraceptives, intrauterine devices, and oral contraceptives.
• People who have had chemotherapy for a known or suspected cancer within the past year.
• People who already have a previously implanted heart device or implantable loop recorder.
• People who have previously had a procedure to close off the left atrial appendage (a small pouch in the heart).
• People who are currently taking part in another randomised clinical trial and are still in the follow-up period.

Important: Always verify eligibility with the trial site directly before applying.